Aveo Oncology Inc., of Cambridge, Mass., signed a research and exclusive option agreement giving Ophthotech Corp., of New York, an exclusive license to investigate the potential of Aveo's small-molecule vascular endothelial growth factor tyrosine kinase inhibitor, tivozanib, outside Asia for the potential treatment of non-oncologic diseases of the eye.